Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

MERCK & CO., INC.

(MRK)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
10/19/2020 10/20/2020 10/21/2020 10/22/2020 10/23/2020 Date
78.67(c) 78.27(c) 78.07(c) 79.21(c) 79.83(c) Last
8 219 894 10 634 329 9 245 995 5 797 777 6 974 613 Volume
-1.45% -0.51% -0.26% +1.46% +0.78% Change
More quotes
Financials (USD)
Sales 2020 48 013 M - -
Net income 2020 11 880 M - -
Net Debt 2020 15 814 M - -
P/E ratio 2020 17,1x
Yield 2020 3,04%
Sales 2021 51 431 M - -
Net income 2021 14 195 M - -
Net Debt 2021 13 391 M - -
P/E ratio 2021 14,3x
Yield 2021 3,25%
Capitalization 202 B 202 B -
EV / Sales 2020 4,53x
EV / Sales 2021 4,19x
Nbr of Employees 71 000
Free-Float 70,6%
More Financials
Company
Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or... 
Sector
Pharmaceuticals
Calendar
10/27 | 11:45amErgebnisveröffentlichung
More about the company
Notations Surperformance© of Merck & Co., Inc.
Trading Rating : Investor Rating :
More Ratings
All news about MERCK & CO., INC.
10/23MERCK : Why Merck Is Playing Catch-Up in the Coronavirus -2-
DJ
10/23Why Merck Is Playing Catch-Up in the Coronavirus Vaccine Chase
DJ
10/23MERCK : Donates $500,000 to Support River Blindness and Lymphatic Filariasis Eli..
AQ
10/23MERCK : PHIL, MERCK Partner to Reach Girls With HPV Vaccine
AQ
10/22MERCK & CO., INC. : quaterly earnings release
10/22MERCK : Donates $500,000 to Support River Blindness and Lymphatic Filariasis Eli..
BU
10/22Covid-19 Vaccine Makers to Face Challenges When Recognizing Revenue
DJ
10/21MERCK : Announces Positive Topline Results from Two Additional Phase 3 Adult Stu..
AQ
10/21SANOFI : Merck and Sanofi to Present Three New Studies Highlighting Combination ..
AQ
10/21MERCK : to Present New Data from its Extensive Infectious Diseases and Vaccines ..
BU
10/20MERCK : and Sanofi to Present Three New Studies Highlighting Combination Pediatr..
PU
10/20MERCK : Reports More Positive Phase 3 Study Results for V114 Vaccine
DJ
10/20MERCK : Announces Positive Topline Results from Two Additional Phase 3 Adult Stu..
BU
10/16MERCK : Presents Three-Year Survival Data for KEYTRUDA® (pembrolizumab) in Combi..
BU
10/16MERCK : FDA Approves Expanded Indication for Merck's KEYTRUDA in Adult Patients ..
AQ
More news
News in other languages on MERCK & CO., INC.
10/22MERCK & CO., INC. : Veröffentlichung des Quartalsergebnisses
10/22MERCK & CO., INC. : publication des résultats trimestriels
10/21MERCK : va partager les résultats de ses recherches
10/20MERCK : essais encourageants du vaccin anti-pneumococcique
10/15MERCK : des progrès dans le traitement du lymphome hodgkinien
More news
Analyst Recommendations on MERCK & CO., INC.
More recommendations
Stock Trading Strategies
MERCK & CO., INC. - 10/14
The underlying trend is to the upside
BUY
More Stock Trading Analysis
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | MarketScreener
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 21
Average target price 96,00 $
Last Close Price 79,83 $
Spread / Highest target 34,0%
Spread / Average Target 20,3%
Spread / Lowest Target 5,22%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Sandy Tremps Vice President-R&D IT CIO
Thomas Henry Glocer Independent Director
Leslie A. Brun Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.-12.23%201 909
JOHNSON & JOHNSON-0.43%382 350
ROCHE HOLDING AG-5.29%280 884
PFIZER INC.-2.55%212 162
NOVARTIS AG-16.78%185 999
NOVO NORDISK A/S15.16%164 690